AEO Dose offers two pharma AI visibility audit tiers priced by scope, not hours or report length: a Free AI Visibility Check covering 2 platforms and 10 buyer questions, and a Full AI Visibility and AEO Readiness Audit covering all 5 platforms (ChatGPT, Gemini, Perplexity, Claude, Grok) with competitive benchmarking. This article explains what each tier covers and which fits which situation.
What AI visibility audit pricing actually buys you
What you buy in an AI visibility audit is coverage: the number of AI platforms tested, the number of buyer questions evaluated, and whether competitive benchmarking is included. You are not buying a report with a page count attached, and you are not buying consultant hours logged against a timesheet. You are buying a measurement of how your company appears when a buyer asks an AI assistant to recommend or compare suppliers.
For a pharma business, that distinction matters. An API manufacturer, a CDMO, an excipient supplier, a nutraceutical brand, and an oral care manufacturer each face buyers who increasingly open ChatGPT or Perplexity before they open a search engine. The question is whether your company surfaces in those answers, and whether the information the AI repeats about you is accurate and complete. The scope of the audit determines how thoroughly that question gets answered.
AEO Dose structures pricing on exactly that basis. The two tiers differ by what they cover, not by how long someone spends writing them up.
The Free AI Visibility Check: 2 platforms, 10 buyer questions
The Free AI Visibility Check tests how your company appears across 2 AI platforms using 10 buyer questions drawn from real procurement patterns. It is a scoped sample, not a full sweep. The purpose is to give you a concrete, grounded read on whether AI assistants mention your company, what they say, and where the obvious gaps are.
The 10 questions are not generic keyword lookups. They are constructed from the kinds of things a buyer actually types: who makes a given API at commercial scale, which CDMO handles a specific dosage form, which excipient supplier carries a particular grade. You see the raw answers, and you see whether your company is present, absent, or misrepresented.
The Free Check is a fit when you want to confirm that a visibility question is worth investigating further. It does not cover all five platforms, and it does not include competitive benchmarking. What it does is establish the baseline: it tells you whether AI assistants know your company exists and describe it correctly on the two platforms tested.
The Full AI Visibility and AEO Readiness Audit: all 5 platforms with competitive benchmarking
The Full AI Visibility and AEO Readiness Audit tests all 5 platforms (ChatGPT, Gemini, Perplexity, Claude, Grok) and adds competitive benchmarking, which the Free Check does not include. Where the Free Check samples, the Full Audit covers the current platform landscape in full and places your visibility next to that of the competitors buyers are comparing you against.
Competitive benchmarking is the structural difference. It is one thing to know an AI assistant does not mention your CDMO. It is another to know which named competitors it recommends when a buyer asks for a supplier in your category. The Full Audit surfaces that gap directly, so you can see not just your own standing but the field you are being measured against.
The Full Audit also produces an AEO readiness assessment: a specific, prioritized set of findings ranked by impact and effort. Rather than a general critique, you get a list of what to fix and in what order, grounded in what the audit actually found across the five platforms. The scope defines the deliverable; there is no need to dress it up beyond what it covers.
Why pricing is structured by scope, not by hours or report length
Pricing is structured by scope because scope is what determines the value of the finding, and hours and report length do not. A longer report is not a better report. More consultant hours do not produce a more accurate reading of how ChatGPT answers a buyer's question about your company. What produces that reading is how many platforms you test and how many realistic buyer questions you run against them.
Hourly billing also misaligns the incentive. It rewards the time spent, not the coverage delivered. Scope-based pricing ties what you pay to what gets measured: 2 platforms and 10 questions, or all 5 platforms with competitive benchmarking. You can see the boundary of each tier before you commit, which is the point of pricing it this way.
This matters for pharma buyers who are used to defined-deliverable procurement. You are not approving an open-ended engagement. You are selecting a coverage level, and the coverage level is the deliverable.
How buyer journey themes shape what gets tested
The questions in an audit are built from five buyer journey themes rather than a static keyword list: discovery, evaluation, product and capability, commercial, and support. Each theme maps to a stage where a buyer might consult an AI assistant about a supplier, and the test questions are drawn from how those stages actually play out in pharma procurement.
Discovery questions ask which suppliers exist in a category. Evaluation questions compare named candidates. Product and capability questions probe specifics: a dosage form, an excipient grade, a manufacturing capacity. Commercial questions touch on terms and sourcing, and support questions cover what happens after a buyer engages.
Building test questions from these themes keeps the audit anchored to real buyer behavior. Current pharma procurement patterns change, and a static keyword list goes stale. Mapping questions to the journey keeps the audit measuring what buyers are actually asking now, not what they asked when a keyword list was last compiled.
Which tier fits which pharma business type
Which tier fits depends on how much you already know about your AI visibility and how competitive your category is, not on your business size. A nutraceutical brand or an oral care manufacturer that has never checked how AI assistants describe it can start with the Free AI Visibility Check to confirm whether a gap exists on the two platforms tested.
An API manufacturer or an excipient supplier in a category with several comparable competitors has more to gain from the competitive benchmarking in the Full Audit, because the relevant question is not only whether AI mentions you, but whether it recommends rivals instead. A CDMO positioning against a defined set of peers is in the same situation: the benchmarking is where the actionable gap shows up.
The honest answer is that the Free Check is a fit when you want a baseline reading, and the Full Audit is a fit when you need the complete platform picture with competitive context. Neither is a better product; they cover different ground.
What happens after the audit: the Audit, Optimize, Build Authority, Measure, Repeat cycle
After the audit, the work follows a cycle: Audit, Optimize, Build Authority, Measure, Repeat. The audit establishes where you stand. Optimization addresses the prioritized findings, starting with the items ranked highest for impact relative to effort. Building authority means strengthening the signals AI assistants rely on when they decide which suppliers to cite.
Measurement re-runs the visibility check so you can see movement against the baseline, and then the cycle repeats as the platform landscape and your competitive position change. Audits turn around in 1 to 2 business days, so the loop from finding to action does not stall at the first step.
This is why the audit is positioned as a starting point rather than a one-off report. The baseline reading is useful, but it is the first stage of a cycle, not the end of one.
If you want a grounded read on where your pharma company currently stands, a baseline check is a low-friction place to begin: Get Your Free AI Visibility Check.
Frequently asked questions
What is included in the Free AI Visibility Check?
The Free AI Visibility Check tests how your company appears across 2 AI platforms using 10 buyer questions drawn from real pharma procurement patterns. You see the raw answers, whether your company is mentioned, what the AI says about it, and where the obvious gaps are. It does not cover all five platforms and does not include competitive benchmarking. Its purpose is to give you a concrete baseline reading on whether AI assistants know your company exists and describe it accurately on the platforms tested.
What does the Full Audit cover that the Free Check does not?
The Full AI Visibility and AEO Readiness Audit tests all 5 platforms (ChatGPT, Gemini, Perplexity, Claude, Grok) rather than 2, and adds competitive benchmarking, which the Free Check does not include. Benchmarking places your visibility next to the competitors buyers compare you against, so you see not only your own standing but the field. The Full Audit also delivers an AEO readiness assessment: a prioritized set of findings ranked by impact and effort, telling you what to fix and in what order.
Why is audit pricing structured by scope rather than by hours?
Pricing is structured by scope because scope determines the value of the finding, while hours and report length do not. A longer report is not more accurate, and more consultant hours do not produce a better reading of how an AI assistant answers a buyer's question. Scope-based pricing ties what you pay to what gets measured: 2 platforms and 10 questions, or all 5 platforms with competitive benchmarking. You see the boundary of each tier before committing, which suits defined-deliverable pharma procurement.
How many AI platforms are tested at each tier?
The Free AI Visibility Check tests 2 AI platforms. The Full AI Visibility and AEO Readiness Audit tests all 5: ChatGPT, Gemini, Perplexity, Claude, and Grok. The difference is deliberate. The Free Check samples enough to establish whether a visibility gap exists, while the Full Audit covers the current platform landscape in full so you can see how you appear everywhere a buyer might ask, rather than on a sample.
What kind of buyer questions are included in the audit?
Audit questions are built from five buyer journey themes: discovery, evaluation, product and capability, commercial, and support. They are not generic keyword lookups. They reflect what a buyer actually asks: who makes a given API at scale, which CDMO handles a dosage form, which excipient supplier carries a specific grade. Mapping questions to the buyer journey keeps the audit anchored to current pharma procurement behavior rather than a static keyword list that goes stale as buyer patterns change.
Does the Full Audit include competitive benchmarking?
Yes. Competitive benchmarking is the structural feature that distinguishes the Full Audit from the Free Check. It places your AI visibility next to the competitors buyers are comparing you against, so you can see whether an assistant recommends named rivals when a buyer asks for a supplier in your category. That gap is where an actionable finding can live, which is why benchmarking is part of the Full Audit scope and not the Free Check sample.
How quickly do audits turn around?
Audits turn around in 1 to 2 business days. After delivery, the work follows a cycle: Audit, Optimize, Build Authority, Measure, Repeat. The audit sets the baseline, optimization addresses the prioritized findings starting with the highest impact relative to effort, authority-building strengthens the signals AI assistants rely on, and measurement re-runs the check to see movement. The fast turnaround means the loop from finding to action does not stall at the first step.
Which tier should my pharma business start with?
Which tier fits depends on how much you already know and how competitive your category is, not on business size. A nutraceutical or oral care brand checking its AI visibility for the first time can start with the Free Check to confirm whether a gap exists. An API manufacturer, excipient supplier, or CDMO competing against a defined set of peers has more to gain from the competitive benchmarking in the Full Audit, because the question is whether AI recommends rivals instead of you.



